Allergy Therapeutics plc has been mentioned in a Form 8.5 (EPT/RI) disclosure by Panmure Gordon (UK) Limited. The disclosure states that Panmure Gordon (UK) Limited, as an exempt principal trader, has made purchases and sales of Allergy Therapeutics' 0.1p ordinary shares. The disclosure provides the total number of securities bought and sold, as well as the highest and lowest prices per unit paid or received.

No cash-settled derivative transactions or stock-settled derivative transactions (including options) are mentioned in the disclosure. Additionally, there are no indemnity or option arrangements, agreements, or understandings relating to relevant securities between Panmure Gordon (UK) Limited and any other party.

The disclosure was made on September 8, 2023, and the contact person for further information is Freddie Wooding, with a telephone number of +44 (0)20 7886 2969.

It's important to note that this disclosure does not provide any information about the business operations, financial performance, or other significant developments of Allergy Therapeutics plc.